Breaking

Creative Diagnostics Launches High-Sensitivity ELISA Kits for Antibiotic Residue Detection in Biologics and Vaccine Manufacturing

Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the release of a specialized portfolio of Antibiotic Residue Detection ELISA Kits. These kits are developed to help biopharmaceutical manufacturers detect and quantify trace levels of antibiotics, such as Gentamicin, Kanamycin, and Neomycin, in biological products, including vaccines, recombinant proteins, and monoclonal antibodies.

Biological products are pharmaceuticals that are prepared through biotechnological processes using microorganisms, cells, animal tissues, and bodily fluids, which are used for the prevention, treatment, and diagnosis of human diseases. This category includes preventive products, (e.g., bacterial and viral vaccines), therapeutic products, (e.g., antitoxins, antisera, blood products, and biotechnology products), and diagnostic products, including in vivo and in vitro products.

Antibiotics are often added to cell culture media during biologics production to prevent microbial contamination. However, international regulatory standards, including the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP), require the removal of these residues during purification to prevent adverse patient reactions, such as ototoxicity and severe allergic responses. These regulatory guidelines also require strict control over antibiotic use in biologics manufacturing and establish testing standards for residual levels.

“Our highly sensitive and reproducible (>80%) antibiotic detection ELISA kits can identify antibiotic residues in raw materials, intermediates, and final products of biologicals. They offer a high-throughput, cost-effective alternative to traditional LC-MS/MS methods,” stated Dr. Jessica Waldorf, senior scientist of Creative Diagnostics. “Our ELISA kits empower manufacturers to ensure their biological products meet stringent safety and purity requirements while achieving reproducible test results.”

For example, Creative Diagnostics offers a Chloramphenicol (CAP) ELISA Test Kit (DEIA6881), which is a competitive enzyme immunoassay for quantitatively analyzing chloramphenicol in fish, shrimp, eggs, honey, meat (beef, chicken and pork), milk, milk powder, condensed milk and serum.

The unique features of the kit are:

1. High recovery (80-115%), rapid extraction (10-40 minutes), and cost-effectiveness.

2. High sensitivity (0.05 ng/g or ppb) and a low detection limit (0.025 ng/g or ppb) for shrimp, fish and meat samples.

3. High reproducibility.

4. A quick ELISA assay (less than 1 hour, regardless of the number of samples).

Chloramphenicol is a broad-spectrum antibiotic widely used in animal production because of its exceptional antibacterial properties and pharmacokinetic characteristics. However, it induces hematotoxic side effects when used in humans, potentially leading to aplastic anemia and granulocytopenia. Consequently, it has been prohibited or restricted in the European Union and the United States. This kit is a novel product based on ELISA technology. Compared to conventional instrumental analysis, it offers rapid operation (less than one hour per test), simplicity, accuracy, and high sensitivity. These features significantly reduce operational error rates and alleviate workload intensity.

To learn more about the ELISA Kit portfolio, visit https://www.creative-diagnostics.com/antibiotic-residues-detection-elisa-kits-in-biological-products.htm.

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers’ assay development and manufacturing needs.

Joseph Wilson

Joseph Wilson is a veteran journalist with a keen interest in covering the dynamic worlds of technology, business, and entrepreneurship.

Recent Posts

New Research Peptide “Pepe-132” Inspired by Ancient New Zealand Frog Demonstrates Promising Anti-Aging Potential in Preclinical Studies

Boston, MA – April 25, 2026 – Apex BioTherapeutics today announced the successful development and…

1 day ago

Human Garage signs 12-show deal with Spark TV to bring self-healing content to mainstream audiences

Partnership with streaming platform marks the movement's entry into long-form wellness entertainment Miami, Fla. —…

2 days ago

Dogecoin Cash, Inc. (OTCQB: DOGP) Publishes Dogecoin Gold White Paper Detailing Digital Asset Framework

MESQUITE, NV — Dogecoin Cash, Inc. (OTCQB: DOGP) (“DOGP” or the “Company”) today announced the…

2 days ago

Berkeley Executive Coaching Institute Earns ICF Level 1 Accreditation for Executive Coaching Certification Program

Accreditation provides BECI graduates a streamlined path to the ICF Associate Certified Coach (ACC) credential,…

2 days ago

Press Release: Memcyco Wins Gold in 2026 Global InfoSec Awards for Best Solution – Account Takeover Protection

San Francisco, California – Memcyco, a leader in real-time digital impersonation and account takeover (ATO)…

2 days ago

CloudBooster Launches Change Control Plane Pilot for AWS Teams

Prague-based company opens applications for early access to its governed lifecycle platform for infrastructure changes…

2 days ago

This website uses cookies.